(Q40030390)

English

Re-examining RAS-blocking treatment regimens for abrogating progression of chronic kidney disease

scientific article published on 4 November 2008

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

16 September 2017

Re-examining RAS-blocking treatment regimens for abrogating progression of chronic kidney disease (English)

1 reference

Europe PubMed Central

PubMed publication ID

16 September 2017

author name string

Murray Epstein

1

1 reference

Europe PubMed Central

PubMed publication ID

16 September 2017

publication date

4 November 2008

1 reference

Europe PubMed Central

PubMed publication ID

16 September 2017

Nature Clinical Practice Nephrology

1 reference

Europe PubMed Central

PubMed publication ID

16 September 2017

5

1 reference

Europe PubMed Central

PubMed publication ID

16 September 2017

1

1 reference

Europe PubMed Central

PubMed publication ID

16 September 2017

12-13

1 reference

Europe PubMed Central

PubMed publication ID

16 September 2017

Renin inhibition: what are the therapeutic opportunities?

1 reference

https://pubmed.ncbi.nlm.nih.gov/18981997

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Combination treatment of angiotensin-II receptor blocker and angiotensin-converting-enzyme inhibitor in non-diabetic renal disease (COOPERATE): a randomised controlled trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/18981997

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial.

1 reference

https://pubmed.ncbi.nlm.nih.gov/18981997

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Telmisartan, ramipril, or both in patients at high risk for vascular events

1 reference

https://pubmed.ncbi.nlm.nih.gov/18981997

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Albuminuria, a therapeutic target for cardiovascular protection in type 2 diabetic patients with nephropathy

1 reference

https://pubmed.ncbi.nlm.nih.gov/18981997

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Renoprotective therapy: titration against urinary protein excretion

1 reference

https://pubmed.ncbi.nlm.nih.gov/18981997

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Aldosterone blockade: an emerging strategy for abrogating progressive renal disease

1 reference

https://pubmed.ncbi.nlm.nih.gov/18981997

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Combination therapy with ACE inhibitors and angiotensin II receptor blockers to halt progression of chronic renal disease: pathophysiology and indications

1 reference

https://pubmed.ncbi.nlm.nih.gov/18981997

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group

1 reference

https://pubmed.ncbi.nlm.nih.gov/18981997

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1038/NCPNEPH0980

1 reference

Europe PubMed Central

PubMed publication ID

16 September 2017

Dimensions Publication ID

0 references

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

16 September 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q40030390&oldid=2203328256"